Talquetamab is an anti-GPRC5DxCD3 BsAb also approved for multiple myeloma, with the notable difference of targeting GPRC5D, an orphan receptor which is expressed on malignant plasma cells, unlike BCMA, which is expressed on malignant and healthy plasma cells, and mature B lymphocytes [49]. Here, TNFRSF17 is linked to AL amyloidosis.